CompaniesAurobindo Pharma LtdFollowAlembic Pharmaceuticals LtdFollowCipla LtdFollowShow more companiesNov 5 (Reuters) – Indian drugmaker Aurobindo Pharma (ARBN.NS), opens new tab reported a 3.8% rise in profit on Wednesday, helped by steady domestic demand, especially for its anti-retroviral drugs for HIV infections.Consolidated net profit in the second quarter rose to 8.48 billion rupees ($96.48 million) from 8.17 billion rupees a year ago.
Sign up here.
Revenue rose 8.37% to 82.86 billion rupees.For further highlights on earnings, click hereKEY CONTEXTIndia’s generic drugmakers get a significant portion of their revenue from North America, where fierce competition has led to lower prices, weighing on their margins. The U.S. contributed 43.9% to Aurobindo’s quarterly consolidated revenue, according to the company’s presentation.U.S. President Donald Trump had levied tariffs on import of branded and patented drugs from October, unless the companies were building a plant in the country. However, the policy had then excluded generic drug imports, offering a reprieve to the sector.Aurobindo Pharma has also gained from strong demand for its anti-retroviral drugs to treat HIV patients.Still, intense competition in the North American generics market continues to pressure drugmakers’ margins.Larger rivals Cipla (CIPL.NS), opens new tab and Dr Reddy’s (REDY.NS), opens new tab posted weak sales in the region this quarter.PEER COMPARISON TABLE:STOCK PERFORMANCE CHART:
Aurobindo Q2FY26($1 = 87.8950 Indian rupees)
Reporting by Mridula Kumar in Benagluru; Editing by Leroy Leo
Our Standards: The Thomson Reuters Trust Principles., opens new tab
